Array Biopharma Inc.

Pharmacia Corporation

Pfizer Corporation

Celgene Corporation

Thesan Pharmaceuticals, Inc.

Medicis Pharmaceutical Corporation

Graceway Pharmaceuticals, LLC

Fbm Therapeutics, LLC

Mark Laurence Boys

Ronald Jay Hinklin

Martha E Rodriguez

Erik James Hicken

Shelley Allen

Mark Joseph Chicarelli

Ellen Ruth Laird

John Peter Fischer

Jay Bradford Fell

James F Blake

Qian Zhao

Huifen Chen

Stephen Douglas Barrett

James Bernard Kramer

John Joseph Gaudino

Thomas Dale Penning

Laurence Edward Burgess

James P Rizzi

Mark Andrew Russell

Adam Wade Cook

Barbara B Chen

George T Topalov

Mark C Munson

John E Robinson

Brad Newhouse

Robert Kirk DeLisle

April L Kennedy

Bryson Rast

Christopher F Kraser

Katerina Leftheris

Balekudru Devadas

Ish K Khanna

Srinivasan Raj Nagarajan

Dale P Spangler

Tony P Tang

Nizal S Chandrakumar

Yoshitaka Satoh

Raj Kumar Raheja

David A Mareska

Brydon L Bennett

Fredrik Pehr Marmsater

Lori A Schretzman

Macedonio J Mejia

Jed Pheneger

Christina Elizabeth Wong

Mohamed S A Elsayed

Robert Andrew Rieger

Yutong Jiang

Michael B Tollefson

Li Ren

David A Moreno

Oren T McNulty

Hwang-Fun Lu

Joshua Ryan Dahlke

Jacob Matthew O'Leary

Scott B Mohler

Alex Andrew Kellum

Patrick Michael Doerner Barbour

John Adam Wendt

Oren Teague Mcnulty

Victoria Leigh Downs

Yaping Wang

Mohamed S Elsayed

Thomas Edward Rogers

Bruce A Lefker

Timothy S Kercher

Alan Frank Gasiecki

Andrew T Metcalf

Bipinchandra N Desai

Robert D Groneberg

Lain-Yen Hu

Darren Martin Harvey

Yi Yu

Lily Huang

Daniel Y Du

Bradley Jon Newhouse

Robert Kirk Delisle

Spencer Phillip Pajk

Renee Huff

Huangshu Lei

William Glen Harter

Eugene Tarlton

Fredrik P Marmsäter

Donna Michele Iula

Yvonne Dorothy Smith

D David Hennings

Albert Khilevich

Nicholas Charles Lazzara

Heather Stenmark

Connor James Cowdrey

Sydney Taylor Blanche

Wesley Dewitt Clark

Ellen Margaret Knapp

Jennifer Lynn Fulton

Faith Elizabeth Witkos

Michael F Bradley

Matthew David Medina

Bryan Daniel Ellis

Hongwei Wu

Hung-Fun Lu

Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

Protein tyrosine phosphatase inhibitors

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

This invention relates to compounds of Formula (I): and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L, L, R, R, Rand n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors

The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R, R, Rand Rare as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.

3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-diones as MEK inhibitors

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X, X, X, R, Rand Rare as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor. 

Bicyclic fused pyridine compounds as inhibitors of TAM kinases

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R, R, Rand Rhave the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R, R, Rand Rhave the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities. 

The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, and Rhave any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF&#x3b2;-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.

Therapeutic pyrazolyl thienopyridines

Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal. 

Growing community of inventors

Boulder, CO, United States of America

Mark Laurence Boys